Products

AHI System
Fifth Eye
Cardiology AI
Fifth Eye's AHI System is an FDA-cleared AI-powered software that provides real-time predictive analytics for hemodynamic instability, detecting patient deterioration hours before vital signs. It uses continuous ECG signals to enhance clinical decision-making and optimize hospital resources.
Analytic for Hemodynamic Instability (AHI)
Fifth Eye
Cardiology AI
Fifth Eye's AHI System is an FDA-cleared, AI-driven clinical decision support software that continuously monitors adult in-hospital patients for signs of hemodynamic instability, providing early warnings hours ahead of traditional vital signs.

See all 2 products →

About Fifth Eye

Fifth Eye is a healthcare AI company that developed the FDA-cleared Analytic for Hemodynamic Instability (AHI) System. This innovative software utilizes non-invasive electrocardiogram (ECG) signals to continuously monitor and predict hemodynamic instability in adult hospital patients, often hours before traditional vital signs would indicate a problem. The technology, which originated from research at the University of Michigan, employs supervised machine learning and advanced signal processing to interpret subtle changes in ECG waveforms, providing clinicians with an early warning of potential patient deterioration.

The AHI System aims to enable proactive clinical intervention, thereby improving patient outcomes, potentially shortening hospital stays, and reducing healthcare costs. It also seeks to alleviate nursing burden by offering real-time surveillance and predictive analytics, helping to prioritize patient care. Fifth Eye was acquired by AirStrip, a leader in clinical surveillance, decision support, and alarm management solutions, on June 2, 2025, and its AHI System now enhances AirStrip’s portfolio by providing predictive insights to care teams.

Focus Areas

AI-powered clinical analytics predictive patient monitoring hemodynamic instability early warning systems ECG signal analysis real-time clinical decision support

Business Intelligence

Key InvestorsInvest Michigan, Biosciences Research and Commercialization Center, Arboretum Ventures, Cultivation Capital, MINTS (University of Michigan's endowment), angel investors
PartnershipsVitalConnect, Medical Informatics Corp.'s Sickbay™ Platform
AcquisitionsAcquired by AirStrip on June 2, 2025
TechnologyAI-driven analytics, machine learning, advanced signal processing, single-lead ECG signals (Lead II), Heart Rate Variability (HRV) patterns, browser-based user interface
FDA Clearances1 cleared products (estimated)

What Physicians Need to Know

AI-Powered Clinical Analytics & Predictive Monitoring
Fifth Eye's AHI Systemu2122 is an FDA-cleared, AI-driven software that continuously analyzes ECG waveforms to predict hemodynamic instability and patient deterioration. It offers predictive insights significantly earlier than traditional vital signs.
Hemodynamic Instability Early Warning
The core specialization is the Analytic for Hemodynamic Instability u2013 Predictive Indicator (AHI-PI), which detects and forecasts the risk of hemodynamic instability. This provides clinicians with an average of over 26 hours of advanced warning before a Rapid Response Team (RRT) event and 48 minutes ahead of vital signs.
ECG Signal Analysis
The technology uniquely leverages continuous ECG lead II data, performing advanced signal processing and extracting Heart Rate Variability (HRV) patterns to non-invasively determine a patient's hemodynamic status.
Real-time Clinical Decision Support
The AHI System provides real-time, continuous monitoring with updates every two minutes, presenting an easy-to-interpret 'traffic-light' (red, yellow, green) risk indicator on a multi-patient dashboard accessible via any browser-enabled device.
Key Differentiators
Fifth Eye stands out as having the only FDA-cleared clinical decision support software of its kind for continuously predicting hemodynamic instability earlier than vital signs. Its ability to use a single ECG lead for comprehensive, non-invasive monitoring and provide a significant lead time for intervention (e.g., 26 hours before RRT events) are major advantages. The underlying machine-learning technology is licensed from the University of Michigan, underscoring its robust research and clinical validation.
Technology Stack
The system is built on AI and supervised machine learning, coupled with advanced signal processing techniques applied to physiologic ECG waveforms. It delivers real-time analytics through a browser-enabled dashboard, allowing access from various devices.
Physician Tip

For physicians, Fifth Eye's AHI System offers the critical advantage of *earlier intervention*, providing a substantial lead time to address patient deterioration before it becomes a crisis, thereby improving patient outcomes and potentially reducing hospital costs. The intuitive 'traffic-light' display and continuous real-time insights enhance *decision support* and allow for more confident prioritization of patient care. By automating continuous monitoring, it significantly *reduces nursing burden* and helps optimize staff allocation, combating burnout. Furthermore, the system's ability to provide *quick feedback on the effectiveness of interventions* can streamline treatment adjustments. Its versatility means it can be applied across various hospital settings, from ICUs to general wards, expanding its utility for a broader patient population.

Fifth Eye's AHI System has established integrations with leading platforms, including Medical Informatics Corp.'s Sickbayu2122 Platform, enhancing patient monitoring and analytics capabilities. Additionally, an agreement with VitalConnect extends its predictive analytics to remote patient monitoring through wearable biosensor technology. As of June 2025, Fifth Eye was acquired by AirStrip, indicating future integration into AirStrip's clinical surveillance, decision support, and alarm management solutions.

Products by Fifth Eye

2 products in the directory

AHI System
Fifth Eye
Cardiology AI
Fifth Eye's AHI System is an FDA-cleared AI-powered software that provides real-time predictive analytics for hemodynamic instability, detecting patient deterioration hours before vital signs. It uses continuous ECG signals to enhance clinical decision-making and optimize hospital resources.
Analytic for Hemodynamic Instability (AHI)
Fifth Eye
Cardiology AI
Fifth Eye's AHI System is an FDA-cleared, AI-driven clinical decision support software that continuously monitors adult in-hospital patients for signs of hemodynamic instability, providing early warnings hours ahead of traditional vital signs.

Reviews & Opinions

No web reviews on file yet for Fifth Eye. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Fifth Eye.

Loading videos...

Videos load interactively. If none appear, search YouTube for Fifth Eye →

View all on YouTube

Press & Coverage

University of Michigan Medical School
Fifth Eye's AHI-PI Demonstrates Ability to Detect Patient Deterioration Prior to Rapid Response Team Events: New Study Published in PLOS Digital Health
A new study published in PLOS Digital Health demonstrates that Fifth Eye's Analytic for Hemodynamic Instability-Predictive Indicator (AHI-PI) can detect patient deterioration an average of 26 hours before Rapid Response Team events, outperforming traditional vital signs.
2024-10
University of Michigan Medical School
Weil Institute spinoff company Fifth Eye, Inc. joins the fight against cancer
Fifth Eye Inc. has been accepted into the 2025 CancerX Accelerator Program to study the predictive capabilities of its AHI analytic in detecting cytokine release syndrome, a dangerous side effect of cancer immunotherapies.
2025-04
Arboretum Ventures
Fifth Eye Receives New Patent to Enhance Breakthrough Patient Monitoring Solution
Fifth Eye has received a new patent to further enhance its patient monitoring solution.
2024-04
PR Newswire
Fifth Eye's AHI System: Detects shock, patient deterioration hours ahead of vital signs
Fifth Eye showcased its AHI System, an advanced predictive patient monitoring technology, at HLTH 2023, highlighting its ability to detect patient deterioration hours before vital signs.
2023-09
AirStrip
AirStrip Acquires Fifth Eye
AirStrip announced its acquisition of Fifth Eye, integrating the FDA-cleared AHI System to provide near real-time prediction of hemodynamic instability and enable earlier clinical intervention.
2025-06
Federal Register
Medical Devices; Cardiovascular Devices; Classification of the Adjunctive Hemodynamic Indicator With Decision Point
The FDA published a final order classifying Fifth Eye Inc.'s Analytic for Hemodynamic Instability (AHI) as a Class II medical device, effective March 1, 2021.
2022-12
Michigan Medicine
Innovative patient stability technology developed at MCIRCC gets FDA market approval
Fifth Eye Inc., a Michigan Medicine spinoff, received FDA De Novo classification for its Analytic for Hemodynamic Instability (AHI), a noninvasive device that continuously monitors ECG signals for early signs of hemodynamic decline.
2021-03
PRWeb
Fifth Eye Inc. Raises $11.5M Series A Funding Round Led by Arboretum Ventures and Cultivation Capital
Fifth Eye Inc., an Ann Arbor-based medical device software company, announced an $11.5 million Series A investment led by Arboretum Ventures and Cultivation Capital to advance its clinical early warning systems for hospitals.
2019-04

Frequently Asked Questions

Fifth Eye's core technology, the Analytic for Hemodynamic Instability (AHI) System, uses AI-powered software to analyze real-time, continuous ECG Lead II data. It extracts heart rate variability (HRV) patterns to detect and predict episodes of hemodynamic instability, often hours before changes are apparent in traditional vital signs. This provides clinicians with an early warning system to intervene proactively.
Fifth Eye primarily offers the AHI System, which includes the AHI Predictive Index (AHI-PI). This FDA-cleared software continuously monitors patients and predicts the likelihood of future hemodynamic instability, displaying risk with a 'traffic-light simplicity' (red, yellow, or green indicator) on a multi-patient screen accessible via browser-enabled devices.
Fifth Eye's AHI System is an FDA-cleared Class II medical device software, complying with regulations for registration, listing, labeling, medical device reporting, and good manufacturing practices (21 CFR Part 807, 801, 803, 820). While specific HIPAA details are not extensively published, medical device software operating in healthcare environments is expected to adhere to HIPAA for the secure handling and transmission of protected health information.
Fifth Eye's AHI System is designed for integration with existing hospital systems. It is available through Medical Informatics Corp.'s Sickbayu2122 Platform and has partnered with VitalConnect to integrate its predictive analytics into VitalConnect's wearable biosensor technology for remote and in-hospital monitoring.
While specific details on Fifth Eye's support and training programs are not publicly detailed in the provided information, it is standard practice for medical device software companies to offer comprehensive implementation support, user training, and ongoing technical assistance to ensure effective adoption and utilization within clinical workflows.
Specific pricing models for Fifth Eye's AHI System are not publicly disclosed in the available information. Typically, pricing for such advanced clinical analytics software in healthcare can vary based on factors like hospital size, number of beds, integration complexity, and the scope of deployment.
Fifth Eye was acquired by AirStrip on June 2, 2025. This acquisition integrates Fifth Eye's AHI System into AirStrip ONE, strengthening AirStrip's clinical surveillance and decision support capabilities. This move suggests enhanced long-term stability and continued product development as part of a larger, established clinical surveillance platform.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.